Figure 4.
Correlation between Cmax and AUC of loncastuximab tesirine–conjugated antibody during cycle 1 and baseline peripheral CD19+ B cells. (A) Cmax. (B) AUC. Linear regression models were used with natural log of baseline peripheral CD19+ B-cell values as the independent variable and natural log of Cmax or AUC as the dependent variable. Zero baseline CD19+ cells was set to 0.1 cells per μL and LN(0.1) = −2.30. The estimated slope (standard error) was −0.0617 (0.0239; 95% CI, −0.109 to −0.0143) for Cmax and −0.232 (0.0370; 95% CI, −0.305 to −0.158) for AUC.

Correlation between Cmax and AUC of loncastuximab tesirine–conjugated antibody during cycle 1 and baseline peripheral CD19+ B cells. (A) Cmax. (B) AUC. Linear regression models were used with natural log of baseline peripheral CD19+ B-cell values as the independent variable and natural log of Cmax or AUC as the dependent variable. Zero baseline CD19+ cells was set to 0.1 cells per μL and LN(0.1) = −2.30. The estimated slope (standard error) was −0.0617 (0.0239; 95% CI, −0.109 to −0.0143) for Cmax and −0.232 (0.0370; 95% CI, −0.305 to −0.158) for AUC.

Close Modal

or Create an Account

Close Modal
Close Modal